{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360846640751297152.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.bbmt.2015.10.009"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1083879115006795?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1083879115006795?httpAccept=text/plain"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380003443990601995","@type":"Researcher","foaf:name":[{"@value":"Kirsten M. Williams"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601984","@type":"Researcher","foaf:name":[{"@value":"Guang-Shing Cheng"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601993","@type":"Researcher","foaf:name":[{"@value":"Iskra Pusic"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601857","@type":"Researcher","foaf:name":[{"@value":"Madan Jagasia"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601998","@type":"Researcher","foaf:name":[{"@value":"Linda Burns"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601997","@type":"Researcher","foaf:name":[{"@value":"Vincent T. Ho"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601996","@type":"Researcher","foaf:name":[{"@value":"Joseph Pidala"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601986","@type":"Researcher","foaf:name":[{"@value":"Jeanne Palmer"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601985","@type":"Researcher","foaf:name":[{"@value":"Laura Johnston"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601990","@type":"Researcher","foaf:name":[{"@value":"Sebastian Mayer"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601856","@type":"Researcher","foaf:name":[{"@value":"Jason W. Chien"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601987","@type":"Researcher","foaf:name":[{"@value":"David A. Jacobsohn"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601989","@type":"Researcher","foaf:name":[{"@value":"Steven Z. Pavletic"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601858","@type":"Researcher","foaf:name":[{"@value":"Paul J. Martin"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601994","@type":"Researcher","foaf:name":[{"@value":"Barry E. Storer"}]},{"@id":"https://cir.nii.ac.jp/crid/1420282801200966144","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"70730349"},{"@type":"NRID","@value":"1000070730349"},{"@type":"NRID","@value":"9000376922974"},{"@type":"NRID","@value":"9000398394051"}],"foaf:name":[{"@value":"Yoshihiro Inamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601991","@type":"Researcher","foaf:name":[{"@value":"Xiaoyu Chai"}]},{"@id":"https://cir.nii.ac.jp/crid/1380003443990601988","@type":"Researcher","foaf:name":[{"@value":"Mary E.D. Flowers"}]},{"@id":"https://cir.nii.ac.jp/crid/1380846640751297152","@type":"Researcher","foaf:name":[{"@value":"Stephanie J. Lee"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10838791"}],"prism:publicationName":[{"@value":"Biology of Blood and Marrow Transplantation"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2016-04","prism:volume":"22","prism:number":"4","prism:startingPage":"710","prism:endingPage":"716"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","http://creativecommons.org/licenses/by-nc-nd/4.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S1083879115006795?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S1083879115006795?httpAccept=text/plain"}],"createdAt":"2015-10-25","modifiedAt":"2025-10-21","project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781864702336","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"15K19563"},{"@type":"JGN","@value":"JP15K19563"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K19563/"}],"notation":[{"@language":"ja","@value":"同種造血細胞移植後の移植片対宿主病の新規バイオマーカーと国際的評価法の研究"},{"@language":"en","@value":"Development of novel biomarkers and international evaluation methods of chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360009142511678592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A case of bronchiolitis obliterans after living-donor renal transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144044606848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145368358528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome after Allogeneic Stem Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network Protocol"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620021945472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620770011648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sparing Effect by Montelukast Treatment for Chronic Graft Versus Host Disease: A Pilot Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621577936768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643742311808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302864777172352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Successful pseudo-autologous stem cell transplantation for donor-derived Burkitt lymphoma occurring 9 years after allogeneic transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094828333952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096062921344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096140721920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Screening with Spirometry Is a Useful Predictor of Later Development of Noninfectious Pulmonary Syndromes in Patients Undergoing Allogeneic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576195053558784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569774724480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial1"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569932435840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Repeated Measures of FEV1 Over Six to Twelve Months: What Change is Abnormal?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593694289024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360863726584580096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Post-transplant obstructive lung disease (\"bronchiolitis obliterans\"): a clinical comparative study of bone marrow and lung transplant patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044844847872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046303043968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521158147200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mechanisms of Airway Obliteration after Lung Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521382700288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993707017728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Maintenance Azithromycin Therapy for Bronchiolitis Obliterans Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993719624832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996192802048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis."}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469104131072","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469160155392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Airflow Obstruction after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469295489664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for Subacute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469889531520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943597036800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchiolitis Obliterans Syndrome Epidemiology after Allogeneic Hematopoietic Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418673452544","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term follow-up of immunosuppressive treatment for obstructive airways disease after allogeneic bone marrow transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418726740480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893569460992","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893571277568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893847990528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894124446080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894572844160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Macrolides in the treatment of bronchiolitis obliterans in allograft recipients"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368731480704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A New Murine Model for Bronchiolitis Obliterans Post–Bone Marrow Transplant"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369326982144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT Reveals Immunobiology of Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843389417344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843614108288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT—a randomized double-blinded placebo-controlled study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844271855104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844840866688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845957480320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Budesonide/Formoterol for Bronchiolitis Obliterans after Hematopoietic Stem Cell Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846177987584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318259939328","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Azithromycin Reverses Airflow Obstruction in Established Bronchiolitis Obliterans Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319480292096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Obstructive Lung Disease after Allogeneic Marrow Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320152292608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of Risk Factors for the Development of Bronchiolitis Obliterans Syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793869357440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation—An Increasingly Recognized Manifestation of Chronic Graft-versus-Host Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796231204352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951796241729280","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Quality of life associated with acute and chronic graft-versus-host disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268465008512","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268666218880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270783978112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"HLA-Specific Antibodies are Risk Factors for Lymphocytic Bronchiolitis and Chronic Lung Allograft Dysfunction"}]},{"@id":"https://cir.nii.ac.jp/crid/1370568466619748864","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reference spirometric values using techniques and equipment that meet ATS recommendations"}]},{"@id":"https://cir.nii.ac.jp/crid/1370568466619748996","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Bronchoalveolar lavage cellular profiles in lung transplantation: the effect of inhaled corticosteroids"}]},{"@id":"https://cir.nii.ac.jp/crid/1370568466619748997","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.bbmt.2015.10.009"},{"@type":"KAKEN","@value":"PRODUCT-20315737"},{"@type":"CROSSREF","@value":"10.1016/j.resinv.2020.12.003_references_DOI_Q8lapCl2pLZ6raEvmGGTplXehYv"},{"@type":"CROSSREF","@value":"10.1016/j.jtct.2021.06.001_references_DOI_Q8lapCl2pLZ6raEvmGGTplXehYv"},{"@type":"CROSSREF","@value":"10.1007/s12185-022-03458-x_references_DOI_Q8lapCl2pLZ6raEvmGGTplXehYv"},{"@type":"CROSSREF","@value":"10.1182/bloodadvances.2021006678_references_DOI_Q8lapCl2pLZ6raEvmGGTplXehYv"},{"@type":"CROSSREF","@value":"10.1016/j.jtct.2021.06.006_references_DOI_Q8lapCl2pLZ6raEvmGGTplXehYv"}]}